Multiple regression analysis for assessing the growth of small hepatocellular carcinoma: the MIB-1 labeling index is the most effective parameter

Saito, Yoshifumi; Matsuzaki, Yasushi; Doi, Mikio; Sugitani, Takehiko; Chiba, Toshiya; Abei, Masato; Shoda, Junichi; Tanaka, Naomi; Saito, Y; Matsuzaki, Y; Doi, M; Sugitani, T; Chiba, T; Abei, M; Shoda, J; Tanaka, N
April 1998
Journal of Gastroenterology;1998, Vol. 33 Issue 2, p229
Academic Journal
journal article
The aim of this study was to clarify whether histological parameters reflected tumor aggressiveness in patients with hepatocellular carcinoma (HCC). The tumor volume doubling times (TVDTs) of 21 HCCs, less than 3 cm in diameter at the start of the observation period, were calculated in 21 patients in whom the natural progression of the lesion was observed by ultrasonography. Paraffin-embedded sections were prepared from samples obtained by ultrasound-guided fine-needle liver biopsy at the end of the observation period. The histological parameters examined were the MIB-1 labeling index (LI), for which we performed immunohistochemical staining with the MIB-1 monoclonal antibody, using an antigen retrieval method; the nucleo-cytoplasmic (N/C ratio), cellularity, and the nuclear form factor (NFF), were calculated with an imaging analyzer. We performed multiple regression analysis for estimating the growth of small HCCs. With the N/C ratio (0.154 +/- 0.068; mean +/- SD), cellularity (453 +/- 21.8 cells/10(4) microm2), NFF (1.150 +/- 0.096), and degree of HCC differentiation as independent variables, only the MIB-1 LI (11.8 +/- 6.1%) showed a significant correlation with TVDT (207.5 +/- 162.6 days) (r = -0.658; P < 0.05). Compared to the conventional indices of histological atypism tested, i.e., N/C ratio, cellularity NFF, and degree of HCC differentiation, only MIB-1 LI was significantly correlated with small HCC growth rate. The MIB-1 LI may therefore be a simple and useful index of tumor aggressiveness.


Related Articles

  • Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase. Panadda Rojpibulstit; Suthathip Kittisenachai; Songchan Puthong; Sirikul Manochantr; Pornpen Gamnarai; Sarawut Jitrapakdee; Sittiruk Roytrakul // Cancer Cell International;2014, Vol. 14 Issue 1, p1 

    Background Hepatocellular carcinoma (HCC) is the most prevalent hepatic cancer worldwide. Currently, a targeted therapy via monoclonal antibodies (mAbs) specific to tumor-associated antigen is undergoing continual development in HCC treatment. Methods In this regard, after establishing and...

  • Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. Endo, Tsunehiro; Yoshikawa, Masaharu; Ebara, Masaaki; Kato, Kazuki; Sunaga, Masahiko; Fukuda, Hiroyuki; Hayasaka, Akira; Kondo, Fukuo; Sugiura, Nobuyuki; Saisho, Hiromitsu // Journal of Gastroenterology;2004, Vol. 39 Issue 12, p1196 

    Background. Metallothionein (MT), which is known to detoxify heavy metal ions, is considered to serve as a mechanism of resistance to platinum complex com- pounds. In the present study, MT expression in hepatocellular carcinoma (HCC) was immunohistologically investigated to clarify its...

  • The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Butler, Samantha L; Dong, Huijia; Cardona, Diana; Jia, Minghong; Zheng, Ran; Zhu, Haizhen; Crawford, James M; Liu, Chen // Laboratory Investigation (00236837);Jan2008, Vol. 88 Issue 1, p78 

    Hepatocyte paraffin 1 (Hep Par 1), a murine monoclonal antibody, is widely used in surgical pathology practice to determine the hepatocellular origin of neoplasms. However, identity of the antigen for Hep Par 1 is unknown. The aim of this study was to characterize the Hep Par 1 antigen. To...

  • Abnormal expression of NRF-2α in hepatocellular carcinoma identified with a newly prepared monoclonal antibody against human NRF-2α protein. Ya Qing Zhang; Kai Nan Li; Ji Hong Cui; Yan Fang Liu; Shou Jing Yang // Molecular Biology Reports;Jun2011, Vol. 38 Issue 5, p3083 

    Human nuclear respiratory factor 2 alpha subunit (NRF-2α) is fundamentally important to cell function and the development. We aimed to establish the monoclonal antibody (MAb) against the human NRF-2α protein and to investigate its distribution in human hepatocellular carcinoma (HCC) and...

  • A case of hepatic angiomyolipoma difficult to distinguish from hepatocellular carcinoma. Takahara, Masahiro; Miyake, Yasuhiro; Matsumoto, Kazuyuki; Kawai, Daisuke; Kaji, Eisuke; Toyokawa, Tatsuya; Nakatsu, Morihito; Ando, Masaharu; Hirohata, Mamoru; Nakajima, Hisato // World Journal of Gastroenterology;6/21/2009, Vol. 15 Issue 23, p2930 

    We report a case of hepatic angiomyolipoma with uncommon clinical features. A 56-year-old man presented with a hepatic tumor in the caudate lobe. The tumor was hypoechoic on ultrasonography, showed early-phase hyperattenuation on enhanced computed tomography and did not absorb iron on...

  • Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. Jianfei Huang; Xialing Zhang; Qi Tang; Feng Zhang; Yuhua Li; Zhenqing Feng; Jin Zhu // Journal of Clinical Pathology;Apr2011, Vol. 64 Issue 4, p343 

    Background Vascular endothelial growth factor receptor 2 (VEGFR2) has been suggested to play an important role in solid tumours. Although several reports have shown the relationship between VEGFR2 expression and hepatocellular carcinoma (HCC), the expression pattern of VEGFR2 in HCC parenchyma...

  • Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Ktade, M.; Uemura, M.; Masaki, T.; Fukui, H. // Gut;Dec2005, Vol. 54 Issue 12, p1768 

    Background: Orchestration of two major classes of angiogenic factors-namely, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2)-has been shown to play a pivotal role in tumour angiogenesis, including hepatocellular carcinoma (HCC). However, few studies have focused on the...

  • Evaluation of 131I-Anti-Angiotensin II Type 1 Receptor Monoclonal Antibody as a Reporter for Hepatocellular Carcinoma. Hao, Pan-Pan; Liu, Yan-Ping; Yang, Chang-Ya; Liang, Ting; Zhang, Chao; Song, Jing; Han, Jian-Kui; Hou, Gui-Hua // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Finding a specific agent is useful for early detection of tumor. Angiotensin II type 1 receptor (AT1R) was reported to be elevated in a variety of tumors and participate in tumor progression. The aim of our study was to evaluate whether 131I-anti-AT1R monoclonal antibody (mAb) is an...

  • Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models. French, Dorothy M.; Lin, Benjamin C.; Wang, Manping; Adams, Camellia; Shek, Theresa; Hötzel, Kathy; Bolon, Brad; Ferrando, Ronald; Blackmore, Craig; Schroeder, Kurt; Rodriguez, Luis A.; Hristopoulos, Maria; Venook, Rayna; Ashkenazi, Avi; Desnoyers, Luc R. // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    The fibroblast growth factor (FGF)-FGF receptor (FGFR) signaling system plays critical roles in a variety of normal developmental and physiological processes. It is also well documented that dysregulation of FGF-FGFR signaling may have important roles in tumor development and progression. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics